CA2255564A1 - Aerodynamically light particles for pulmonary drug delivery - Google Patents

Aerodynamically light particles for pulmonary drug delivery

Info

Publication number
CA2255564A1
CA2255564A1 CA002255564A CA2255564A CA2255564A1 CA 2255564 A1 CA2255564 A1 CA 2255564A1 CA 002255564 A CA002255564 A CA 002255564A CA 2255564 A CA2255564 A CA 2255564A CA 2255564 A1 CA2255564 A1 CA 2255564A1
Authority
CA
Canada
Prior art keywords
aerodynamically light
light particles
particles
amino acid
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002255564A
Other languages
French (fr)
Other versions
CA2255564C (en
Inventor
David A. Edwards
Giovanni Caponetti
Jeffrey S. Hrkach
Noah Lotan
Justin Hanes
Abdell Aziz Ben-Jebria
Robert S. Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute Of Technology
David A. Edwards
Giovanni Caponetti
Jeffrey S. Hrkach
Noah Lotan
Justin Hanes
Abdell Aziz Ben-Jebria
Robert S. Langer
The Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27096992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2255564(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Institute Of Technology, David A. Edwards, Giovanni Caponetti, Jeffrey S. Hrkach, Noah Lotan, Justin Hanes, Abdell Aziz Ben-Jebria, Robert S. Langer, The Penn State Research Foundation filed Critical Massachusetts Institute Of Technology
Publication of CA2255564A1 publication Critical patent/CA2255564A1/en
Application granted granted Critical
Publication of CA2255564C publication Critical patent/CA2255564C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

Improved aerodynamically light particles for delivery to the pulmonary system, and methods for their preparation and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of a biodegradable material and have a tap density less than 0.4 g/cm3 and a mass mean diameter between 5 µm and 30 µm. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear .alpha.-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter for example greater than 5 µm, can be used for enhanced delivery of a therapeutic or diagnostic agent to the alveolar region of the lung. The aerodynamically light particles optionally can incorporate a therapeutic or diagnostic agent, and may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide variety of incrorporated agents.
CA002255564A 1996-05-24 1997-05-23 Aerodynamically light particles for pulmonary drug delivery Expired - Lifetime CA2255564C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65557096A 1996-05-24 1996-05-24
US655570 1996-05-24
US739308 1996-10-29
US08/739,308 US5874064A (en) 1996-05-24 1996-10-29 Aerodynamically light particles for pulmonary drug delivery
PCT/US1997/008895 WO1997044013A1 (en) 1996-05-24 1997-05-23 Aerodynamically light particles for pulmonary drug delivery

Publications (2)

Publication Number Publication Date
CA2255564A1 true CA2255564A1 (en) 1997-11-27
CA2255564C CA2255564C (en) 2006-08-29

Family

ID=27096992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002255564A Expired - Lifetime CA2255564C (en) 1996-05-24 1997-05-23 Aerodynamically light particles for pulmonary drug delivery

Country Status (10)

Country Link
US (6) US5874064A (en)
EP (1) EP0907356B1 (en)
JP (2) JP4315468B2 (en)
AT (1) ATE215357T1 (en)
CA (1) CA2255564C (en)
DE (1) DE69711626T2 (en)
DK (1) DK0907356T3 (en)
ES (1) ES2175420T3 (en)
PT (1) PT907356E (en)
WO (1) WO1997044013A1 (en)

Families Citing this family (581)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL103238A (en) * 1991-09-25 1995-07-31 Fisons Plc Pressurised aerosol compositions
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US6652837B1 (en) * 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
WO1998027980A2 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
WO1998029098A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US7779020B2 (en) * 2002-03-01 2010-08-17 International Business Machines Corporation Small-footprint applicative query interpreter method, system and program product
JP2001510151A (en) 1997-07-18 2001-07-31 インファイムド，インク． Biodegradable macromers for controlled release of bioactive substances
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
WO1999029758A1 (en) * 1997-12-12 1999-06-17 Samyang Corporation Positively-charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
US6958148B1 (en) * 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
CA2231968A1 (en) * 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Method of producing a nicotine medicament
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
EP1273290A1 (en) * 1998-06-24 2003-01-08 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
AU747231B2 (en) * 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
MA25590A1 (en) 1998-09-14 2002-12-31 Inhale Therapeutic Syst ACTIVE AGENT FOR DRY POWDER DELIVERY
US8933032B2 (en) 1998-10-20 2015-01-13 Children's Hospital Medical Center Surfactant protein D for the treatment of disorders associated with lung injury
DK1158958T3 (en) * 1999-03-05 2007-10-08 Chiesi Farma Spa Improved powder formulation for inhalation
US20050214227A1 (en) * 1999-03-08 2005-09-29 Powderject Research Limited Microparticle formulations for sustained-release of bioactive compounds
CA2370539C (en) 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
WO2000074736A1 (en) * 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
PT1808438E (en) * 1999-06-29 2015-01-14 Mannkind Corp Purification and stabilization of peptide and proteins in pharmaceutical agents
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
CA2382821A1 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US6156294A (en) 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6676930B2 (en) 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6761909B1 (en) * 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
WO2001045731A1 (en) * 1999-12-21 2001-06-28 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
HUP0204136A3 (en) * 1999-12-30 2005-09-28 Chiron Corp Emeryville Methods for pulmonary delivery of interleukin-2
AU2001226029A1 (en) 2000-01-10 2001-07-24 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
US7029700B2 (en) * 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
US7833549B2 (en) * 2000-01-19 2010-11-16 Mannkind Corporation Dry powder formulations of antihistamine for nasal administration
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2001055217A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
AU4724401A (en) 2000-02-28 2001-09-12 Genesegues Inc Nanocapsule encapsulation system and method
JP2003525061A (en) * 2000-03-01 2003-08-26 メディミューン，インコーポレイテッド High potency recombinant antibody and method for producing the same
JP2003525946A (en) * 2000-03-08 2003-09-02 マサチューセッツ インスティテュート オブ テクノロジー Heparinase III and uses thereof
AU4920701A (en) * 2000-03-14 2001-09-24 Nat Jewish Med & Res Center Method for reducing allergen-induced airway hyperresponsiveness
WO2001085136A2 (en) * 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
AU2001277230A1 (en) * 2000-08-01 2002-02-13 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution andparticles made thereby
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
CA2422059C (en) 2000-09-12 2012-05-15 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
CA2423469A1 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
GB0028268D0 (en) * 2000-11-20 2001-01-03 Norske Stats Oljeselskap Well treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
JP4434580B2 (en) 2000-11-28 2010-03-17 メディミューン，エルエルシー Methods for administering / prescribing anti-RSV antibodies for prevention and treatment
DE60140268D1 (en) * 2000-11-30 2009-12-03 Vectura Ltd PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION
US20020159954A1 (en) * 2000-12-01 2002-10-31 Parker Small Aerodynamically light vaccine for active pulmonary immunization
US20020128179A1 (en) * 2000-12-01 2002-09-12 Tacon William C. Shaped microparticles for pulmonary drug delivery
EP2354149B1 (en) 2000-12-12 2017-08-30 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7981420B2 (en) 2000-12-22 2011-07-19 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
EP1345968A2 (en) * 2000-12-28 2003-09-24 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
CA2433335C (en) * 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US6749845B2 (en) * 2001-02-15 2004-06-15 Aeropharm Technology, Inc. Modulated release particles for lung delivery
US6848197B2 (en) * 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
AP1763A (en) * 2001-05-21 2007-08-02 Nektar Therapeutics Pulmonary administration of chemically modified insulin
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7458374B2 (en) * 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US6737043B2 (en) 2001-05-24 2004-05-18 Alexza Molecula Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US7766013B2 (en) * 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
WO2002100357A1 (en) * 2001-06-12 2002-12-19 Trial Corporation Cosmetic
WO2003000014A2 (en) * 2001-06-21 2003-01-03 Altus Biologics, Inc. Spherical protein particles and methods of making and using them
US6730772B2 (en) * 2001-06-22 2004-05-04 Venkatram P. Shastri Degradable polymers from derivatized ring-opened epoxides
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US6921390B2 (en) * 2001-07-23 2005-07-26 Boston Scientific Scimed, Inc. Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface
DE10137102A1 (en) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalent vaccine against diseases caused by papillomaviruses, processes for their production and their use
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
EP1446104B2 (en) 2001-11-01 2011-08-03 Novartis AG Spray drying methods
CN1607941A (en) * 2001-11-19 2005-04-20 贝克顿迪肯森公司 Pharmaceutical compositions in particulate form
WO2003043603A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
AU2002352836B2 (en) * 2001-11-20 2005-09-29 Alkermes, Inc. Improved particulate compositions for pulmonary delivery
WO2003043586A2 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
US20030168057A1 (en) * 2001-12-14 2003-09-11 Inhale Therapeutic Systems, Inc. Electronically controllable aerosol delivery
JP2005514393A (en) * 2001-12-19 2005-05-19 ネクター セラピューティクス Supplying aminoglycosides to the lung
EP1480691A4 (en) * 2002-03-05 2007-11-28 Univ State Cleveland Agglomerated particles for aerosol drug delivery
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
CN101143221A (en) * 2002-03-15 2008-03-19 布赖汉姆妇女医院 Central airway administration for systemic delivery of therapeutics
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
EP1485068A2 (en) * 2002-03-20 2004-12-15 Advanced Inhalation Research, Inc. hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
DK2630954T3 (en) 2002-03-20 2017-01-23 Civitas Therapeutics Inc PULMONAL SUBMISSION OF LEVODOPA
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
AU2003213955A1 (en) * 2002-04-05 2003-10-27 Valorisation - Recherche, Societe En Commandite Functionalized polymers and their biomedical and pharmaceutical uses
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
WO2003092654A1 (en) 2002-05-02 2003-11-13 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
EP1503744A1 (en) 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2003256823B9 (en) * 2002-07-25 2009-01-08 Medimmune, Llc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
DE10234165B4 (en) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale A method of filling a trench formed in a substrate with an insulating material
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
EP2298806A1 (en) 2002-10-16 2011-03-23 Purdue Pharma L.P. Antibodies that bind cell-associated CA 125/0722P and methods of use thereof
US6800663B2 (en) * 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
CN1717237A (en) 2002-11-26 2006-01-04 艾利斯达分子传输公司 Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US20040206350A1 (en) * 2002-12-19 2004-10-21 Nektar Therapeutics Aerosolization apparatus with non-circular aerosolization chamber
WO2004058218A2 (en) * 2002-12-30 2004-07-15 Nektar Therapeutics Prefilming atomizer
PL378270A1 (en) * 2002-12-31 2006-03-20 Nektar Therapeutics Pharmaceutical formulation with an insoluble active agent for pulmonary administration
CA2511555A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1596804A4 (en) 2003-01-13 2008-02-06 Macrogenics Inc SOLUBLE FcyR FUSION PROTEINS AND METHODS OF USE THEREOF
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
WO2004073729A1 (en) 2003-02-21 2004-09-02 Translational Research Ltd. Compositions for nasal administration of drug
WO2004087243A1 (en) 2003-03-27 2004-10-14 Bioactis Limited Powder medicine applicator for nasal cavity
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
PT1610850E (en) * 2003-04-09 2012-06-15 Novartis Ag Aerosolization apparatus with air inlet shield
KR20110094361A (en) 2003-04-11 2011-08-23 메디뮨 엘엘씨 Recombinant il-9 antibodies and uses thereof
ATE520935T1 (en) 2003-05-21 2011-09-15 Alexza Pharmaceuticals Inc USE OF A SOLID FUEL LAYER, METHOD FOR PRODUCING SUCH A LAYER AND ASSOCIATED HEATING DEVICE
GB0313604D0 (en) * 2003-06-12 2003-07-16 Britannia Pharmaceuticals Ltd Delivery device for powdered medicament
JP2007517537A (en) * 2003-06-13 2007-07-05 アドバンスト インハレーション リサーチ，インコーポレイテッド Low dosage pharmaceutical powder for inhalation
WO2004112799A1 (en) * 2003-06-13 2004-12-29 Chrysalis Technologies Incorporated Methods and apparatus for producing nanoscale particles
US20050032173A1 (en) * 2003-08-05 2005-02-10 Mauricio Rojas Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
EP1659918B1 (en) 2003-08-08 2009-01-14 Amgen Fremont Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
JP2007505136A (en) * 2003-09-10 2007-03-08 マツプ・フアーマシユーテイカルズ・インコーポレーテツド Aerosol formulation for delivering dihydroergotamine to systemic circulation by pulmonary inhalation
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
EP1667659A1 (en) * 2003-09-30 2006-06-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
EP1675571A2 (en) * 2003-09-30 2006-07-05 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
WO2005044226A2 (en) * 2003-11-04 2005-05-19 Nectar Therapeutics Lipid formulations for spontaneous drug encapsulation
EP1708738B1 (en) * 2004-01-12 2016-05-04 MannKind Corporation A method of reducing serum proinsulin levels in type 2 diabetics
US20060019914A1 (en) * 2004-02-11 2006-01-26 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
PT2319500E (en) * 2004-03-12 2013-01-23 Biodel Inc Rapid acting drug delivery compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
AU2005244128B2 (en) * 2004-05-07 2009-06-25 President And Fellows Of Harvard College Pulmonary malarial vaccine
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US20060078506A1 (en) * 2004-05-20 2006-04-13 Ralph Niven Methods, systems and devices for noninvasive pulmonary delivery
US7540286B2 (en) * 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
BRPI0512326A (en) * 2004-06-21 2008-02-26 Nektar Therapeutics compositions comprising amphotericin b, methods and systems
US8513204B2 (en) * 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
US20060147520A1 (en) * 2004-07-26 2006-07-06 Curtis Ruegg Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
WO2006016530A1 (en) * 2004-08-10 2006-02-16 Translational Research, Ltd. Transnasal composition having immediate action and high absorbability
US20100006092A1 (en) * 2004-08-12 2010-01-14 Alexza Pharmaceuticals, Inc. Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages
AU2004322756B2 (en) * 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
JP5078014B2 (en) 2004-08-20 2012-11-21 マンカインド コーポレイション Catalytic reaction of diketopiperazine synthesis.
HUE026797T2 (en) 2004-08-23 2016-07-28 Mannkind Corp Diketopiperazine salts for drug delivery
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
JP2008518936A (en) * 2004-10-29 2008-06-05 メディミューン，インコーポレーテッド Methods for preventing and treating RSV infections and related conditions
DE102004053373A1 (en) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Invention relating to nano / meso-fiber anisometric particles in the form of nano / meso-fiber tubes, cables and their curved or branched modifications
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
US8627821B2 (en) 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
EP1848410A4 (en) * 2005-02-17 2011-11-09 Medivas Llc Polymer particle delivery compositions and methods of use
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
ES2707152T3 (en) 2005-04-15 2019-04-02 Macrogenics Inc Covalent diabodies and uses thereof
US8028697B2 (en) 2005-04-28 2011-10-04 Trudell Medical International Ventilator circuit and method for the use thereof
KR20080018872A (en) * 2005-05-18 2008-02-28 풀매트릭스 인코퍼레이티드 Formulations for alteration of biophysical properties of mucosal lining
US20110177996A1 (en) * 2005-05-23 2011-07-21 Children's Hospital Medical Center Regulatory proteins in lung repair and treatment of lung disease
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
CN101379085B (en) * 2005-06-30 2013-03-27 Abbvie公司 IL-12/P40 binding proteins
US7919583B2 (en) * 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
AU2006279700A1 (en) * 2005-08-11 2007-02-22 President And Fellows Of Harvard College Methods and compositions for dried cellular forms
EP2500359A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
KR20120060245A (en) 2005-09-14 2012-06-11 맨카인드 코포레이션 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US8445007B2 (en) 2005-09-22 2013-05-21 Medivas, Llc Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use
CA2623239C (en) * 2005-09-22 2016-07-12 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2007036501A2 (en) * 2005-09-26 2007-04-05 Basf Aktiengesellschaft Graft copolymer and use of the same
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
AU2006297394B9 (en) * 2005-09-29 2013-09-19 Novartis Ag Receptacles and kits, such as for dry powder packaging
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
CA2624562A1 (en) * 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
JP2009514902A (en) * 2005-11-11 2009-04-09 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． Solid pharmaceutical composition comprising aggregated nanoparticles and method for producing the same
WO2008048298A2 (en) * 2005-11-21 2008-04-24 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
US8691224B2 (en) * 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
KR20180058863A (en) 2005-11-30 2018-06-01 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
EP1962894A4 (en) * 2005-12-07 2012-11-14 Medivas Llc Method for assembling a polymer-biologic delivery composition
JP2009519970A (en) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド Process for producing particle-based pharmaceutical dosage forms for oral administration
WO2007070851A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
EP2497484A3 (en) * 2006-02-22 2012-11-07 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
WO2007123777A2 (en) * 2006-03-30 2007-11-01 Duke University Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
AU2007240986A1 (en) * 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
US7718609B2 (en) * 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20090317335A1 (en) * 2006-04-20 2009-12-24 Wenbin Lin Hybrid Nanomaterials as Multimodal Imaging Contrast Agents
WO2007130477A2 (en) * 2006-05-02 2007-11-15 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
WO2007133616A2 (en) * 2006-05-09 2007-11-22 Medivas, Llc Biodegradable water soluble polymers
ES2599319T3 (en) 2006-06-26 2017-02-01 Macrogenics, Inc. Fc RIIB specific antibodies and their methods of use
EP2064243A2 (en) 2006-08-28 2009-06-03 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
MY188368A (en) 2006-09-08 2021-12-06 Abbott Lab Interleukin-13 binding proteins
EP2407548A1 (en) 2006-10-16 2012-01-18 MedImmune, LLC Molecules with reduced half-lives, compositions and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008078730A1 (en) 2006-12-26 2008-07-03 Translational Research, Ltd. Preparation for transnasal application
AU2008214359B2 (en) 2007-02-05 2014-01-16 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
EP2425819A1 (en) 2007-02-11 2012-03-07 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
EP2152304B1 (en) 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
ES2540807T3 (en) 2007-05-04 2015-07-13 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Variable domains of rabbit antibodies modified by genetic engineering and uses thereof
US20090175847A1 (en) * 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP3424951A1 (en) 2007-06-21 2019-01-09 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2009015143A1 (en) * 2007-07-24 2009-01-29 Medivas, Llc Biodegradable cationic polymer gene transfer compositions and methods of use
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc Multispecific epitope binding proteins and uses thereof
GB0715376D0 (en) * 2007-08-07 2007-09-19 Smith & Nephew Coating
JP5270884B2 (en) * 2007-09-03 2013-08-21 大阪瓦斯株式会社 Dispersant and polylactic acid based composite resin particles containing the dispersant
EP2033971A1 (en) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
MX2010007342A (en) * 2008-01-04 2010-08-26 Biodel Inc Insulin formulations for insulin release as a function of tissue glucose levels.
US20110105995A1 (en) * 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
WO2009092011A1 (en) 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
US20110135571A1 (en) * 2008-02-22 2011-06-09 Wenbin Lin Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
PL2265309T3 (en) * 2008-03-17 2016-06-30 Discovery Lab Inc Ventilation circuit adaptor and proximal aerosol delivery system
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2009136382A2 (en) * 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
EP2285345A1 (en) * 2008-05-15 2011-02-23 Novartis AG Pulmonary delivery of a fluoroquinolone
JP2011523853A (en) 2008-06-03 2011-08-25 アボット・ラボラトリーズ Dual variable domain immunoglobulins and uses thereof
KR20110016959A (en) 2008-06-03 2011-02-18 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP3281663B8 (en) 2008-06-13 2022-09-21 MannKind Corporation Breath powered dry powder inhaler for drug delivery
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
WO2009155450A2 (en) * 2008-06-20 2009-12-23 Board Of Regents, The University Of Texas System Biodegradable photoluminescent polymers
RU2559525C2 (en) 2008-07-08 2015-08-10 Эббви Инк Proteins binding prostaglandin e2 and using them
SG192489A1 (en) * 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
WO2010008564A2 (en) * 2008-07-16 2010-01-21 Recombinetics Plaice dna transposon system
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
EP2323671A4 (en) * 2008-08-13 2012-09-26 Medivas Llc Aabb-poly(depsipeptide) biodegradable polymers and methods of use
CN102223876A (en) * 2008-09-26 2011-10-19 纳米生物公司 Nanoemulsion therapeutic compositions and methods of using the same
ES2402241T3 (en) 2008-10-22 2013-04-30 Trudell Medical International Modular Spray Supply System
EP2376089B1 (en) 2008-11-17 2018-03-14 The Regents of the University of Michigan Cancer vaccine compositions and methods of using the same
RU2011127198A (en) * 2008-12-04 2013-01-10 Эбботт Лэборетриз IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION
JP5734201B2 (en) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド Covalently bonded diabody and use thereof
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
RU2011135768A (en) * 2009-01-29 2013-03-10 Эбботт Лэборетриз PROTEINS BINDING IL-1
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP2398461A1 (en) * 2009-02-18 2011-12-28 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US8030026B2 (en) * 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
PE20121094A1 (en) 2009-03-05 2012-09-13 Abbvie Inc IL-17 BINDING PROTEINS
US8283162B2 (en) * 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
EP2413902B1 (en) 2009-03-18 2019-07-17 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP2410981B2 (en) 2009-03-26 2020-02-26 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2010111132A2 (en) 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
DE102009016119A1 (en) * 2009-04-03 2010-10-14 Evonik Degussa Gmbh Nutritional supplement containing alpha-keto acids to support diabetes therapy
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
AU2010254551B2 (en) 2009-05-27 2016-10-20 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
EP3556356B1 (en) * 2009-06-12 2021-05-05 MannKind Corporation Diketopiperazine microparticles with defined isomer content
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
UY32808A (en) * 2009-07-29 2011-02-28 Abbott Lab IMMUNOGLOBULINS AS A DUAL VARIABLE DOMAIN AND USES OF THE SAME
GB2472327B (en) * 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
JP5762408B2 (en) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー Antibodies against human respiratory syncytial virus (RSV) and methods of use
EP2470568A2 (en) 2009-08-29 2012-07-04 Abbott Laboratories Therapeutic dll4 binding proteins
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP5898082B2 (en) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド Fc region-containing polypeptide exhibiting improved effector function by changing the degree of fucosylation and use thereof
BR112012008833A2 (en) 2009-10-15 2015-09-08 Abbott Lab double variable domain immunoglobulins and uses thereof
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
UY32979A (en) * 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
US8449916B1 (en) * 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
SG10201501562VA (en) 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
NZ602054A (en) 2010-03-17 2014-10-31 Abbott Res Bv Anti-nerve growth factor (ngf) antibody compositions
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
AU2011249782B2 (en) 2010-05-06 2014-10-02 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
ES2659406T3 (en) 2010-05-06 2018-03-15 Novartis Ag Compositions and methods of use for therapeutic antibodies against protein 6 related to low density lipoproteins (LRP6)
UY33386A (en) 2010-05-14 2011-12-30 Abbott Laboratoires IL-1 UNION PROTEINS
CA2798323A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
KR101768118B1 (en) 2010-06-25 2017-08-14 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Methods and pharmaceutical compositions for the treatment of respiratory tract infections
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CN103097412B (en) 2010-07-09 2016-08-10 克鲁塞尔荷兰公司 Anti-human respiratory syncytial virus (RSV) antibody and using method
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
CN103154025B (en) 2010-08-02 2015-07-01 宏观基因有限公司 Covalent diabodies and uses thereof
MX341579B (en) 2010-08-03 2016-08-25 Abbvie Inc * Dual variable domain immunoglobulins and uses thereof.
CN103298833B (en) 2010-08-14 2015-12-16 Abbvie公司 Amyloid beta associated proteins
PL3333188T3 (en) 2010-08-19 2022-05-09 Zoetis Belgium S.A. Anti-ngf antibodies and their use
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
CN103080134B (en) 2010-08-20 2015-11-25 诺华股份有限公司 The antibody of EGF-R ELISA 3 (HER3)
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
US9084944B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
PT2611529T (en) 2010-09-03 2019-05-09 Bend Res Inc Spray-drying method
EP2618924A1 (en) 2010-09-24 2013-07-31 Bend Research, Inc. High-temperature spray drying process and apparatus
RU2017144619A (en) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. CASES OF SINGLE-VALVE METALS OF DRY POWDERS FOR INHALATIONS
PT3470057T (en) 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Cationic dry powders comprising magnesium salt
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
TW201307388A (en) 2010-12-21 2013-02-16 Abbott Lab IL-1 binding proteins
CN105667994B (en) 2011-04-01 2018-04-06 曼金德公司 Blister package for pharmaceutical kit
RU2625034C2 (en) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Antibodies and other molecules binding b7-h1 and pd-1
MX347818B (en) 2011-05-21 2017-05-15 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103796667A (en) 2011-06-22 2014-05-14 艾普莱斯制药公司 Methods of treating chronic disorders with complement inhibitors
CN103619910B (en) 2011-06-23 2016-08-31 帝斯曼知识产权资产管理有限公司 The novel polyester-amide copolymer delivered for medicine
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
JP6049712B2 (en) 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ Metal bisphosphonate nanoparticles for anti-cancer treatment and imaging and bone disorder treatment
KR20140061403A (en) 2011-07-13 2014-05-21 애브비 인코포레이티드 Methods and compositions for treating asthma using anti-il-13 antibodies
JP2014526886A (en) 2011-07-15 2014-10-09 モルフォシス・アー・ゲー Antibodies cross-reactive with macrophage migration inhibitory factor (MIF) and D-dopachrome tomerase (D-DT)
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
WO2013063095A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
KR20140095483A (en) 2011-10-24 2014-08-01 맨카인드 코포레이션 Methods and compositions for treating pain
RS58919B1 (en) 2011-12-02 2019-08-30 Integrated Biotherapeutics Inc Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
JP6243345B2 (en) 2011-12-05 2017-12-06 ノバルティス アーゲー Antibody to epidermal growth factor receptor 3 (HER3)
KR20140103135A (en) 2011-12-05 2014-08-25 노파르티스 아게 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
WO2013090635A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
WO2013090633A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
KR20140103939A (en) 2011-12-16 2014-08-27 노파르티스 아게 Aerosolization apparatus for inhalation profile-independent drug delivery
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
NZ625403A (en) 2012-01-27 2016-03-31 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
WO2013149013A1 (en) 2012-03-28 2013-10-03 Discovery Laboratories, Inc. Lyophilization of synthetic liposomal pulmonary surfactant
BR112014025518B1 (en) 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Aggregate particles of umeclidinium, vilanterol and fluticasone, powder composition, inhaler, process for preparing aggregate particles, and, use of magnesium stearate in aggregate particles
CA2871745C (en) 2012-05-03 2023-01-24 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
KR102140989B1 (en) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9585970B2 (en) 2012-06-04 2017-03-07 Novartis Ag Site-specific labeling methods and molecules produced thereby
JP6629069B2 (en) 2012-06-06 2020-01-15 ゾエティス・エルエルシー Canine anti-NGF antibody and method thereof
UY34905A (en) 2012-07-12 2014-01-31 Abbvie Inc IL-1 UNION PROTEINS
DK2872205T3 (en) 2012-07-12 2017-02-27 Mannkind Corp DRY POWDER FORMAL ADMINISTRATION SYSTEM
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
TW202210507A (en) 2012-11-01 2022-03-16 美商艾伯維有限公司 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
BR112015010722A2 (en) 2012-11-09 2017-08-22 Pfizer SPECIFIC GROWTH FACTOR ANTIBODIES DERIVED FROM ISOFORM B PLATELETS AND COMPOSITIONS AND USES THEREOF
US10034988B2 (en) 2012-11-28 2018-07-31 Fontem Holdings I B.V. Methods and devices for compound delivery
WO2014100439A2 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
BR112015014621A2 (en) 2012-12-21 2017-10-03 Amplimmune Inc ANTI-H7CR ANTIBODIES
CA2899032A1 (en) 2013-02-01 2014-08-07 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
AU2014214751B2 (en) 2013-02-08 2017-06-01 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
JP6669499B2 (en) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド Therapeutic compounds
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP2016510000A (en) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド Therapeutic compounds and uses thereof
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
CA2906417C (en) 2013-03-14 2022-06-21 Robert Ziemann Hcv core lipid binding domain monoclonal antibodies
BR112015023239A8 (en) 2013-03-14 2018-04-17 Abbott Lab hcv antibody-antigen combination assay and methods and compositions for use thereof
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
CN105007950B (en) 2013-03-15 2019-01-15 诺华股份有限公司 Antibody drug conjugate
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
KR102499439B1 (en) 2013-03-15 2023-02-13 맨카인드 코포레이션 Microcrystalline diketopiperazine compositions and methods
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
WO2014178891A1 (en) 2013-04-30 2014-11-06 Otitopic Inc. Dry powder formulations and methods of use
WO2014190356A2 (en) 2013-05-24 2014-11-27 Amplimmune, Inc. Anti-b7-h5 antibodies and their uses
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
ES2753419T3 (en) 2013-06-07 2020-04-08 Univ Duke Complement factor H inhibitors
PT3010535T (en) 2013-06-19 2020-07-03 Integrated Biotherapeutics Inc Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
WO2015010092A1 (en) 2013-07-18 2015-01-22 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
JP2016530930A (en) 2013-08-05 2016-10-06 マンカインド コーポレイション Ventilation device and method
UA116479C2 (en) 2013-08-09 2018-03-26 Макродженікс, Інк. Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
KR20160055275A (en) 2013-09-17 2016-05-17 유니버시티 헬스 네트워크 Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in the methods of treatment
US10194693B2 (en) 2013-09-20 2019-02-05 Fontem Holdings 1 B.V. Aerosol generating device
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (en) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. Crystalline forms of therapeutic compounds and uses thereof
WO2015066480A1 (en) 2013-11-01 2015-05-07 Regents Of The University Of Minnesota Protein scaffolds and methods of use
WO2015069926A1 (en) 2013-11-06 2015-05-14 The University Of Chicago Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
KR102366076B1 (en) 2013-11-13 2022-02-21 화이자 인코포레이티드 Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
TW201536320A (en) 2013-12-02 2015-10-01 Abbvie Inc Compositions and methods for treating osteoarthritis
EP3094348A4 (en) 2014-01-14 2017-07-12 Integrated Biotherapeutics, Inc. Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
CA2939556A1 (en) 2014-02-14 2015-08-20 Andrew S. Chi Improved methods for the treatment of vascularizing cancers
WO2015127315A1 (en) 2014-02-20 2015-08-27 Otitopic Inc. Dry powder formulations for inhalation
EP3450571B1 (en) 2014-02-24 2023-04-05 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20150291689A1 (en) 2014-03-09 2015-10-15 Abbvie, Inc. Compositions and Methods for Treating Rheumatoid Arthritis
BR112016020065A2 (en) 2014-03-12 2018-02-20 Novartis Ag specific sites to modify antibodies to make immunoconjugates
KR20220025946A (en) 2014-03-21 2022-03-03 애브비 인코포레이티드 Anti-egfr antibodies and antibody drug conjugates
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
WO2015175874A2 (en) 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
CN107257691B (en) 2014-07-16 2021-09-21 达娜-法勃肿瘤研究所公司 HER3 inhibition in low-grade serous ovarian cancer
CA2991760A1 (en) 2014-07-31 2016-02-04 Otitopic Inc. Dry powder formulations for inhalation
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
PE20170903A1 (en) 2014-08-12 2017-07-12 Novartis Ag DRUG CONJUGATES WITH ANTI-CDH6 ANTIBODIES
WO2016036960A1 (en) 2014-09-03 2016-03-10 Genesegues, Inc. Therapeutic nanoparticles and related compositions, methods and systems
UY36316A (en) 2014-09-26 2016-04-29 Macrogenics Inc MONOVALENT BIESPECFIC DIACUMS THAT ARE ABLE TO JOIN CD19 AND CD3, AND USES OF THE SAME
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
JP7158853B2 (en) 2014-10-10 2022-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン An immunogenic composition for treating food or respiratory allergies in a subject and for intranasal administration to said subject
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
JP6731404B2 (en) 2014-10-14 2020-07-29 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiation therapy, chemotherapy, immunotherapy, and any combination thereof
CA2962719A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
CN107106641B (en) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 Powder formulation
MA40910A (en) 2014-11-07 2017-09-12 Civitas Therapeutics Inc RAPAMYCIN POWDERS FOR PULMONARY ADMINISTRATION
KR20170087500A (en) 2014-12-11 2017-07-28 피에르 파브르 메디카먼트 Anti-C10ORF54 antibodies and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3229803B1 (en) 2014-12-12 2020-01-29 Massachusetts General Hospital Treatment of breast cancer brain metastases
WO2016097297A1 (en) 2014-12-18 2016-06-23 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
WO2016118921A1 (en) 2015-01-24 2016-07-28 Abbvie, Inc. Compositions and methods for treating psoriatic arthritis
KR20170105622A (en) 2015-01-26 2017-09-19 마크로제닉스, 인크. A multivalent molecule comprising a DR5-binding domain
WO2016120828A1 (en) 2015-01-30 2016-08-04 Novartis Ag Treatment of breast cancer by m-csf antagonist
FI3265123T3 (en) 2015-03-03 2023-01-31 Antibodies, uses & methods
EP3303395B1 (en) 2015-05-29 2019-12-11 AbbVie Inc. Anti-cd40 antibodies and uses thereof
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
JP2018524346A (en) 2015-07-02 2018-08-30 サイヴィタス セラピューティックス，インコーポレイテッド Triptan powder for pulmonary delivery
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
LT3328419T (en) 2015-07-30 2021-11-10 Macrogenics, Inc. Pd-1-binding molecules and methods of use thereof
CN108473576A (en) 2015-09-11 2018-08-31 艾伯维公司 Method for the multiple sclerosis for treating recurrence form
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
JP6968787B2 (en) 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. Dosing regimen
MX2018004177A (en) 2015-10-08 2018-09-11 Macrogenics Inc Combination therapy for the treatment of cancer.
US10138298B2 (en) 2015-10-23 2018-11-27 The Regents Of The University Of California Anti-IL-2 antibodies and compositions and uses thereof
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
ES2861449T3 (en) 2015-12-02 2021-10-06 Stcube & Co Inc Antibodies and Molecules that Immunospecifically Bind to BTN1A1 and Their Therapeutic Uses
KR20180100122A (en) 2015-12-02 2018-09-07 주식회사 에스티사이언스 Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor)
EP3389714A4 (en) 2015-12-14 2019-11-13 MacroGenics, Inc. Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
IL260335B2 (en) 2016-02-01 2023-10-01 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
TW201730212A (en) 2016-02-17 2017-09-01 宏觀基因股份有限公司 ROR1-binding molecules, and methods of use thereof
LT3423105T (en) 2016-03-02 2021-09-10 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
IL262396B2 (en) 2016-04-15 2023-09-01 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
CA3023257A1 (en) 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
US11246877B2 (en) 2016-05-20 2022-02-15 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
EP3464372A1 (en) 2016-06-01 2019-04-10 AbbVie Inc. Anti-repulsive guidance molecule a (rgma) antagonistic antibodies for treating spinal cord injury and pain
EA201892595A1 (en) * 2016-06-03 2019-06-28 М Эт П Фарма Аг NAZAL PHARMACEUTICAL COMPOSITIONS WITH POROUS FILLER
JP2019526529A (en) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド Anti-B7-H3 antibody and antibody drug conjugate
PE20190177A1 (en) 2016-06-08 2019-02-01 Abbvie Inc ANTI-B7-H3 ANTIBODIES AND ANTIBODY AND DRUG CONJUGATES
CN109562169A (en) 2016-06-08 2019-04-02 艾伯维公司 Anti-CD 98 antibody and antibody drug conjugates
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324251A1 (en) 2016-09-08 2019-03-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
TW201818933A (en) 2016-10-21 2018-06-01 美商吉利亞洛吉克斯公司 Compositions and methods for the treatment of neurodegenerative and other diseases
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP3544628A4 (en) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
WO2018111580A1 (en) 2016-12-13 2018-06-21 Emory University Polypeptides for managing viral infections
JOP20190155A1 (en) 2016-12-21 2019-06-23 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
EP3558368A4 (en) 2016-12-23 2020-12-30 MacroGenics, Inc. Adam9-binding molecules, and methods of use thereof
RU2019123307A (en) 2017-01-20 2021-02-20 М Эт П Фарма Аг Nasal Pharmaceutical Compositions to Reduce Risks of Exposure to Air Pollutants
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
JOP20190187A1 (en) 2017-02-03 2019-08-01 Novartis Ag Anti-ccr7 antibody drug conjugates
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
US11932694B2 (en) 2017-04-19 2024-03-19 Bluefin Biomedicine, Inc. Anti-VTCN1 antibodies and antibody drug conjugates
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
EP3621616A4 (en) 2017-05-10 2021-01-13 InCarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2018273887B2 (en) 2017-05-22 2022-09-08 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof
US20200148768A1 (en) 2017-05-31 2020-05-14 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
KR20200026209A (en) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand
MX2019015007A (en) 2017-06-13 2020-08-06 Integrated Biotherapeutic Vaccines Inc Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides.
CN111194232B (en) 2017-08-02 2023-01-31 芝加哥大学 Nanoscale metal-organic layer and metal-organic nanosheet
WO2019049862A1 (en) * 2017-09-05 2019-03-14 味の素株式会社 Polylysine derivative
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
WO2019106578A2 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
MX2020005662A (en) 2017-12-01 2020-08-20 Pfizer Anti-cxcr5 antibodies and compositions and uses thereof.
KR20200141986A (en) 2018-02-12 2020-12-21 다이어비티스-프리, 인크. Improved antagonistic anti-human CD40 monoclonal antibody
US20210001062A1 (en) * 2018-03-08 2021-01-07 University Of Washington Devices, systems, and methods for delivery of a reperfusion-injury-modifying drug to a patient
EP3765499A1 (en) 2018-03-12 2021-01-20 Zoetis Services LLC Anti-ngf antibodies and methods thereof
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
MX2020010183A (en) 2018-03-29 2022-11-28 Pfizer Lfa3 variants and compositions and uses thereof.
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
US20190314324A1 (en) 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
EP3801766A1 (en) 2018-05-31 2021-04-14 Novartis AG Hepatitis b antibodies
TW202015739A (en) 2018-06-01 2020-05-01 日商衛材R&D企管股份有限公司 Splicing modulator antibody-drug conjugates and methods of use
PE20210320A1 (en) 2018-06-01 2021-02-16 Novartis Ag BINDING MOLECULES AGAINST BCMA AND THE USES OF THEM
UY38265A (en) 2018-06-20 2020-01-31 Novartis Ag DRUG ANTIBODY CONJUGATES FOR ABLATION OF HEMATOPOIETIC STEM CELLS
US20210268070A1 (en) 2018-07-10 2021-09-02 Rush University Medical Center Use of Immunomodulators to Control Infection and Stimulate Healing in Normal and Diabetic Wounds
EP3824287A1 (en) 2018-07-20 2021-05-26 Pierre Fabre Médicament Receptor for vista
CN112703000A (en) 2018-07-23 2021-04-23 特雷维治疗股份有限公司 Treatment of chronic cough, shortness of breath and dyspnea
BR112021004287A2 (en) 2018-09-07 2021-08-03 Pfizer Inc. anti-avss8 antibodies and compositions and uses thereof
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
EP3883961A1 (en) 2018-11-20 2021-09-29 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
PE20211473A1 (en) 2018-12-13 2021-08-05 Eisai Randd Man Co Ltd ANTIBODY-HERBOXIDIENE DRUG CONJUGATES AND METHODS OF USE
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
PE20211296A1 (en) 2018-12-21 2021-07-20 Novartis Ag ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF
EP3911739A1 (en) 2019-01-16 2021-11-24 University Of Rochester Improvement of epithelial or endothelial barrier function
CA3132959A1 (en) 2019-03-08 2020-09-17 AbTis Co., Ltd. Site-specific antibody conjugation and antibody-drug conjugate as specific embodiment thereof
CA3140063A1 (en) 2019-05-20 2020-11-26 Novartis Ag Antibody drug conjugates having linkers comprising hydrophilic groups
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
EP4041767A1 (en) 2019-09-26 2022-08-17 StCube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
JP2022552282A (en) 2019-10-09 2022-12-15 エスティーキューブ アンド カンパニー Antibodies specific for glycosylated LAG3 and methods of use thereof
MX2022005221A (en) 2019-11-07 2022-06-08 Eisai R&D Man Co Ltd Anti-mesothelin eribulin antibody-drug conjugates and methods of use.
JP7449390B2 (en) 2020-01-24 2024-03-13 ファイザー・インク Anti-E-selectin antibodies, compositions and methods of use
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
EP4138884A1 (en) 2020-04-20 2023-03-01 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
US20230167193A1 (en) 2020-05-01 2023-06-01 Novartis Ag Immunoglobulin variants
EP4143236A1 (en) 2020-05-01 2023-03-08 Novartis AG Engineered immunoglobulins
WO2021239935A1 (en) 2020-05-29 2021-12-02 Universität Zu Köln Neutralizing antibodies against sars-related coronavirus
AR122546A1 (en) 2020-06-05 2022-09-21 Eisai R&D Man Co Ltd ANTI-BCMA-DRUG ANTIBODY CONJUGATES AND METHODS OF USE
US11746154B2 (en) 2020-10-09 2023-09-05 Pfizer Inc. CD1a antibodies and uses thereof
GB202017058D0 (en) 2020-10-27 2020-12-09 Kymab Ltd Antibodies and uses thereof
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
CN116472288A (en) 2020-11-06 2023-07-21 诺华股份有限公司 Antibody Fc variants
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CR20230283A (en) 2020-11-24 2023-07-27 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
EP4259200A1 (en) 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
GB202101125D0 (en) 2021-01-27 2021-03-10 Kymab Ltd Antibodies and uses thereof
BR112023021475A2 (en) 2021-04-16 2023-12-19 Novartis Ag ANTIBODY-DRUG CONJUGATES AND METHODS FOR PRODUCING THEM
WO2023073599A1 (en) 2021-10-28 2023-05-04 Novartis Ag Engineered fc variants
GB202117111D0 (en) 2021-11-26 2022-01-12 Kymab Ltd Antibodies for use as therapeutics against bacterial infections
EP4190810A1 (en) 2021-12-01 2023-06-07 Universität zu Köln Neutralizing antibodies against sars-related coronavirus
WO2023099688A1 (en) 2021-12-01 2023-06-08 Universität Zu Köln Neutralizing antibodies against sars-related coronavirus
WO2023114375A2 (en) * 2021-12-16 2023-06-22 Alveolus Bio, Inc. Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024028731A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Transferrin receptor binding proteins for treating brain tumors
WO2024028732A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Cd98 binding constructs for treating brain tumors

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533065A (en) * 1947-03-08 1950-12-05 George V Taplin Micropulverized therapeutic agents
US2470296A (en) * 1948-04-30 1949-05-17 Abbott Lab Inhalator
US2992645A (en) * 1958-05-06 1961-07-18 Benger Lab Ltd Disperser for powders
US3957965A (en) * 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
AU439432B2 (en) * 1968-11-28 1972-08-15 Dulux Australia Ltd Polymer and coating composition
US4173488A (en) * 1968-12-23 1979-11-06 Champion International Corporation Oil-in-water emulsions containing hydropholeic starch
US3781230A (en) * 1968-12-23 1973-12-25 Champion Int Corp Microcapsular opacifier system
GB1410588A (en) * 1971-08-10 1975-10-22 Fisons Ltd Composition
US4089800A (en) * 1975-04-04 1978-05-16 Ppg Industries, Inc. Method of preparing microcapsules
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4743545A (en) * 1984-08-09 1988-05-10 Torobin Leonard B Hollow porous microspheres containing biocatalyst
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4276885A (en) * 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
ATE23272T1 (en) * 1981-07-08 1986-11-15 Draco Ab POWDER INHALER.
DE3268533D1 (en) * 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
DE3141641A1 (en) * 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen ULTRASONIC CONTRAST AGENTS AND THEIR PRODUCTION
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4865789A (en) * 1983-11-14 1989-09-12 Akzo Nv Method for making porous structures
AU565354B2 (en) * 1983-11-14 1987-09-10 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4679555A (en) * 1984-08-07 1987-07-14 Key Pharmaceuticals, Inc. Method and apparatus for intrapulmonary delivery of heparin
SE459005B (en) * 1985-07-12 1989-05-29 Aake Rikard Lindahl SET TO MANUFACTURE SPHERICAL POLYMER PARTICLES
WO1987003197A1 (en) * 1985-11-29 1987-06-04 Fisons Plc Pharmaceutical composition including sodium cromoglycate
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US5160745A (en) * 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
ES2053549T3 (en) * 1986-08-11 1994-08-01 Innovata Biomed Ltd A PROCESS FOR THE PREPARATION OF AN APPROPRIATE PHARMACEUTICAL FORMULATION FOR INHALATION.
DE3779221D1 (en) 1986-08-19 1992-06-25 Genentech Inc DEVICE AND DISPERSION FOR THE INTRAPULMONAL ENTERING OF POLYPEPTIDE GROWTH SUBSTANCES AND CYTOKINS.
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
DE3637926C1 (en) * 1986-11-05 1987-11-26 Schering Ag Ultrasonic manometry in a liquid using microbubbles
JPS63122620A (en) * 1986-11-12 1988-05-26 Sanraku Inc Polylactic acid microsphere and production thereof
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US4855144A (en) * 1987-10-23 1989-08-08 Advanced Polymer Systems Synthetic melanin aggregates
IE61591B1 (en) * 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
JP2670680B2 (en) * 1988-02-24 1997-10-29 株式会社ビーエムジー Polylactic acid microspheres containing physiologically active substance and method for producing the same
AU3073789A (en) * 1988-03-31 1989-10-05 Abbott Laboratories Drug delivery using pulmonary surfactant to facilitate absorption
US5064650A (en) * 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US4917119A (en) * 1988-11-30 1990-04-17 R. J. Reynolds Tobacco Company Drug delivery article
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US4976968A (en) * 1989-02-24 1990-12-11 Clinical Technologies Associates, Inc. Anhydrous delivery systems for pharmacological agents
DE69024953T3 (en) * 1989-05-04 2005-01-27 Southern Research Institute, Birmingham encapsulation
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
DK0494996T3 (en) * 1989-10-03 1996-03-18 Advanced Polymer Systems Inc Erodable macroporous hydrogel particles and their preparation
IT1237118B (en) * 1989-10-27 1993-05-18 Miat Spa MULTI-DOSE INHALER FOR POWDER DRUGS.
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
AU634606B2 (en) * 1989-11-06 1993-02-25 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
JP2571874B2 (en) * 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド Protein microsphere composition
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5123414A (en) * 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
GB9003821D0 (en) * 1990-02-20 1990-04-18 Danbiosyst Uk Diagnostic aid
AU636481B2 (en) * 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
SE9002017D0 (en) * 1990-06-06 1990-06-06 Kabivitrum Ab PROCESS FOR MANUFACTURE OF MATRICES
WO1992000061A1 (en) 1990-06-29 1992-01-09 Fisons Plc Pressurised aerosol compositions
AU639137B2 (en) * 1990-09-21 1993-07-15 Merrell Dow Pharmaceuticals Inc. Superior tasting pharmaceutical composition having porous particles and the process of preparing such pharmaceutical composition
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
SE9302777D0 (en) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5327883A (en) * 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5558857A (en) * 1991-06-03 1996-09-24 Nycomed Imaging As Contrast agents
DE69208660T2 (en) * 1991-06-10 1996-07-11 Schering Corp FLUORINE CHLORINE HYDROGEN-FREE AEROSOL FORMULATIONS
ATE359842T1 (en) 1991-07-02 2007-05-15 Nektar Therapeutics DISPENSING DEVICE FOR MIST-FORMED MEDICATIONS
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
DE69232034T2 (en) 1991-12-18 2002-06-06 Minnesota Mining & Mfg Aerosol compositions for drug suspensions
US5169871A (en) * 1991-12-19 1992-12-08 Hoechst Celanese Corp. Highly porous compressible polymeric powders
JPH07507806A (en) * 1992-06-11 1995-08-31 アルカーメス　コントロールド　セラピューティクス，インコーポレイテッド Erythropoietin drug delivery system
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
PT679088E (en) * 1992-09-29 2002-12-31 Inhale Therapeutic Syst PULMONARY ADMINISTRATION OF ACTIVE FRAGMENTS OF PARTIROID HORMONE
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
CZ191695A3 (en) * 1993-01-25 1996-05-15 Sonus Pharma Inc Biologically compatible contrast agent, process of its preparation and representation method by ultrasound
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE4323636A1 (en) * 1993-07-15 1995-01-19 Hoechst Ag Pharmaceutical preparations from coated, poorly water-soluble pharmaceutical substances for inhalation pharmaceutical forms and processes for their preparation
DE59409568D1 (en) * 1993-09-09 2000-11-30 Schering Ag ACTIVE SUBSTANCES AND GAS CONTAINING MICROPARTICLES
ATE209903T1 (en) * 1993-10-01 2001-12-15 Astrazeneca Ab PROCEDURE I
AU689217B2 (en) * 1994-03-07 1998-03-26 Novartis Ag Methods and compositions for pulmonary delivery of insulin
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
JPH10506406A (en) * 1994-09-29 1998-06-23 アンダリス、リミテッド Spray-dried fine particles as therapeutic vehicles
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
CA2225914A1 (en) * 1995-06-29 1997-01-16 Pharmacopeia, Inc. Combinatorial 1,4-benzodiazepin-2,5-dione library
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery

Also Published As

Publication number Publication date
ATE215357T1 (en) 2002-04-15
PT907356E (en) 2002-07-31
US6942868B2 (en) 2005-09-13
DE69711626D1 (en) 2002-05-08
US6136295A (en) 2000-10-24
ES2175420T3 (en) 2002-11-16
US20020141947A1 (en) 2002-10-03
US6399102B1 (en) 2002-06-04
JP2006160767A (en) 2006-06-22
CA2255564C (en) 2006-08-29
US6635283B2 (en) 2003-10-21
US20040047811A1 (en) 2004-03-11
US20050158249A1 (en) 2005-07-21
DE69711626T2 (en) 2002-10-24
EP0907356A1 (en) 1999-04-14
JP2000511189A (en) 2000-08-29
JP4489716B2 (en) 2010-06-23
US5874064A (en) 1999-02-23
JP4315468B2 (en) 2009-08-19
DK0907356T3 (en) 2002-07-29
WO1997044013A1 (en) 1997-11-27
EP0907356B1 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
CA2255564A1 (en) Aerodynamically light particles for pulmonary drug delivery
CA2167921A1 (en) Biodegradable particles
EP0501523B1 (en) Bioadhesive compositions
CA2336139A1 (en) Large porous particles emitted from an inhaler
US5225196A (en) Bioadhesive compositions and methods of treatment therewith
WO1993025583A3 (en) Proteinoid carriers and methods for preparation and use thereof
EP1518550A3 (en) Bioadhesive drug delivery systems comprising poly(fumaric-co-sebacic acid)
WO1997002810A3 (en) Polymeric lamellar substrate particles for drug delivery
WO2002043705A3 (en) Aerodynamically light vaccine for active pulmonary immunization
ATE287257T1 (en) PREPARATION OF PARTICLE-CONTAINING MEDICINAL PRODUCTS FOR INHALATION
DE69121675D1 (en) Pharmaceutical composition containing microsphere with controlled release and method of manufacture
DE69425932T2 (en) Rapidly dissolving pharmaceutical dosage forms and methods for their manufacture
CA2219698A1 (en) Sustained-release preparation
CA2212309A1 (en) Extended-release solid oral dosage forms of drugs having low solubility in water
CA2219777A1 (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
DE69736396D1 (en) Spherical particles, process for their preparation and pharmaceutical compositions with these
CA2324254A1 (en) Sustained-release composition including amorphous polymer
CA2273272A1 (en) Immediate release drug delivery forms
DE69522038D1 (en) Biodegradable copolymer, biodegradable polymer composition, biodegradable product and their manufacture
Moskvina Determination of Structural Parameters of Microcracks in Oriented Polymers--Polyethylene Terephthalate, Polycarbonate, Polyamide-6
CA1260832A (en) Bioadhesive compositions and methods of treatment therewith
CA2134082A1 (en) Bioadhesive microspheres and their use as drug delivery and imaging systems
Seguela Processing- structure- property relationships in polymeric materials
Sone et al. Acetal Copolymer and Method of Producing the Same
Chiyuujiyou LCP blends

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170523